RW: Registration Withdrawal Request
Published on March 22, 2016
HedgePath Pharmaceuticals, Inc.
324 S. Hyde Park Avenue, Ste. 350
Tampa, Florida 33606
March 22, 2016
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 3561
Washington, D.C. 20549
Attention: Ruairi J. Regan, Esq.
Re: | HedgePath Pharmaceuticals, Inc. |
Registration Statement on Form S-1 (File No. 333-208594), filed on December 17, 2015
Ladies and Gentlemen:
Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the Securities Act), HedgePath Pharmaceuticals, Inc. (the Company) hereby requests that the Securities and Exchange Commission (the Commission) consent to the withdrawal of the above-referenced registration statement on Form S-1, together with all exhibits and amendments thereto (collectively, the Registration Statement) effective as of the date hereof. The Company is requesting withdrawal of the Registration Statement because it does not plan to pursue a public offering at this time. The Company believes that such withdrawal is consistent with the public interest and the protection of investors as contemplated by paragraph (a) of Rule 477.
The Registration Statement was not declared effective by the Commission under the Securities Act. The Company hereby confirms that no securities have been or will be issued or sold pursuant to the Registration Statement or the prospectus contained therein and no preliminary prospectus contained in the Registration Statement has been distributed. The Company requests that, in accordance with Rule 457(p) under the Securities Act, all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use by the Company.
Should you have any questions or require anything further, please feel free to contact Mr. Garrison Hasara, the Companys Chief Financial Officer, at (813) 864-2560.
Very truly yours, |
HedgePath Pharmaceuticals, Inc. |
/s/ Nicholas J. Virca |
Nicholas J. Virca |
President Chief Executive Officer |
cc: Lawrence A. Rosenbloom, Esq. |